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PregnantBackground: Early RSV illness is associated with wheeze-associated disorders in childhood. Candidate
respiratory syncytial virus (RSV) vaccines may prevent acute RSV illness in infants. We investigated
the feasibility of maternal RSV vaccine trials to demonstrate reductions in recurrent childhood wheezing
in general paediatric populations.
Methods: We calculated vaccine trial effect sizes that depended on vaccine efficacy, allocation ratio, rate
of early severe RSV illness, risk of recurrent wheezing at age 3, and increased risk of RSV infection on
recurrent wheezing. Model inputs came from systematic reviews and meta-analyses. For each combina-
tion of inputs, we estimated the sample size required to detect the effect of vaccination on recurrent
wheezing.
Results: There were 81 scenarios with 1:1 allocation ratio. Risk ratios between vaccination and recurrent
wheezing ranged from 0.9 to 1.0 for 70% of the scenarios. Among the 57 more plausible scenarios, the
lowest sample size required to detect significant reductions in recurrent wheezing was 6196 mother-
infant pairs per trial arm; however, 75% and 47% of plausible scenarios required >31,060 and >100,000
mother-infant pairs per trial arm, respectively. Studies with asthma endpoints at age 5 will likely need
to be larger.01, USA.
accina-
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tion during pregnancy to prevent recurrent chiDiscussion: Clinical efficacy trials of candidate maternal RSV vaccines undertaken for licensure are unli-
kely to demonstrate an effect on recurrent wheezing illness due to the large sample sizes likely needed to
demonstrate a significant effect. Further efforts are needed to plan for alternative study designs to esti-
mate the impact of maternal RSV vaccine programs on recurrent childhood wheezing in general
populations.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The development of safe and effective vaccines to protect young
children against respiratory syncytial virus (RSV) illness is a global
health priority [1,2]. RSV is a major cause of lower respiratory
infections (LRI) among young children globally [3,4]. While nearly
all children will have been infected by RSV by two years of age [5],
the infections during the first months of life can be the most severe
[6]. In addition to its acute effects, early childhood RSV illness has
been associated with subsequent development of wheeze-
associated disorders later in life [7,8]. Vaccination of pregnant
women against RSV may protect their infants against RSV illness
during their first months of life, primarily through maternal anti-
bodies transported across the placenta [1]. While licensure of
RSV vaccines for use during pregnancy is likely to be sought for
the primary indication of preventing acute RSV illness in young
infants, the public health value of maternal RSV vaccines would
be greater if the vaccine also prevented wheeze-associated disor-
ders [1]. Studies to assess the effects of RSV prevention on these
childhood respiratory outcomes have been recommended by
experts convened by the Bill & Melinda Gates Foundation [7], the
Lancet [9], and the World Health Organization (WHO) [2].
However, the sample sizes required to detect an effect on such out-
comes in randomized clinical trials (RCTs) have not been
calculated.
Wheeze-associated disorders in childhood are a common cause
of morbidity globally. Wheezing can be severe and can lead to
decreased quality of life, frequent healthcare utilization, and high
economic costs in young children [9–12]. Recurrent wheezing
may resolve as children age, but for others, the symptoms can per-
sist [10,12]. The diagnosis of asthma as a cause of recurrent wheez-
ing cannot be objectively made using lung function until about
5 years of age [7,10]. Definitions for recurrent childhood wheezing
typically include multiple episodes of wheezing since birth among
children younger than 5 years of age [8,13,14].
In 2017, the WHO Initiative for Vaccine Research assembled a
technical working group to estimate the sample size required for
RCTs of RSV vaccination during pregnancy to demonstrate an effect
on recurrent childhood wheezing. This report describes the output
of the deliberations. The goal of the work was to inform public
health expectations and planning for maternal RSV vaccines, so
the working group focused on studies in general communities,
rather than in high-risk subgroups.2. Methods
2.1. Study design
We estimated the RCT sample size that would be required to
demonstrate an effect of RSV vaccination during pregnancy on
recurrent childhood wheezing through 3 years of age. We chose
this endpoint because recurrent childhood wheezing is an impor-
tant cause of paediatric morbidity [10,12]. Additionally, RCTs with
recurrent childhood wheezing as a primary endpoint will likely be
more favourable than other childhood respiratory outcomes for
several reasons. First, an outcome that could be assessed at aanjan Bhat, Louis J. Bont et al.,
ldhood wheezing: A sample sizyounger age is advantageous, because longer trials have higher
rates of losses to follow-up and are more costly. Second, recurrent
wheezing at 3 years is expected to have a higher prevalence than
asthma at 5 years [12,15], increasing the statistical power for a
given sample size. Third, if some portion of asthma at 5 years is
caused by early infant RSV exposure, it is plausible that recurrent
wheezing at 3 years mediates this relationship. Fourth, atopy and
environmental risk factors are more likely to be found in children
with asthma than in children with recurrent wheeze [9,14,16,17],
indicating that early RSV illness may contribute a larger attributa-
ble fraction to recurrent childhood wheezing at 3 years than to
asthma at 5 years.
We based our approach on an earlier study that estimated the
detectable risks in observational studies of potential foetal benefits
of maternal influenza vaccination [18]. The approach is described
in the following illustrative example. Suppose that 1000 mother-
infant pairs were randomized to each arm of a placebo-
controlled RCT of a maternal RSV vaccine. If the baseline risk of
vaccine-preventable early infant RSV illness in the population is
r, then approximately 1000  r infants born to women in the pla-
cebo arm will acquire RSV illness during the vaccine-preventable
period. In the vaccine arm, prevention of infant RSV illness is
proportional to the vaccine efficacy (%), VE, implying that
1000  r  (1  VE) infants born to women immunized against
RSV will acquire an RSV illness. Supposing an attack rate of 20%
(r) and vaccine efficacy of 50% (VE), we would expect 200 cases
(= 1000  0.2) of RSV illness among infants in the placebo arm
and 100 cases (=1000  0.2  0.5) of RSV illness among infants in
the vaccine arm.
We considered infant RSV illness within the first months to be a
mediator on the causal pathway of maternal RSV vaccine protec-
tion against recurrent childhood wheezing since these early RSV
illnesses occur within the vaccine-preventable time frame and
are associated with the highest acute morbidity (Fig. 1). That is,
the ability of RSV vaccination during pregnancy to prevent later
recurrent childhood wheezing would operate through the reduc-
tion in early RSV illness during the first months of life. If the base-
line risk of recurrent wheezing at 3 years, w, is 5% among infants
who do not experience an early RSV illness, and 20% among those
who do, this would imply a 4-fold relative increase in the risk
resulting in a risk ratio RRRW of 4. (The subscript RW is used to
denote the risk ratio of RSV illness associated with wheezing ill-
ness). In the placebo arm, applying these risks to the 200 and
800 infants with and without RSV illness, respectively, results in
80 total cases of recurrent wheezing among infants in the placebo
arm ((200  0.20 + (800  0.05)). Among infants born to RSV-
vaccinated mothers, 900 will have a 5% risk of developing the
recurrent wheezing, and 100 will have a 20% risk, for a total of
65 cases ((900  0.05) + (100  0.2)). In this hypothetical scenario,
maternal RSV immunization reduced the risk of childhood wheez-
ing from 80 per 1000 (placebo arm) to 65 per 1000 (vaccine arm),
for a risk ratio associated with vaccination (RRVW) of 0.81 (= 65 per
1000  80 per 1000) (Fig. 2). (The subscript VW is used to denote
the risk ratio of vaccine associated with wheezing illness, or the
vaccine effect size). We used estimates from the literature supple-
mented by expert opinion to inform the following parameterInforming randomized clinical trials of respiratory syncytial virus vaccina-
e analysis, Vaccine, https://doi.org/10.1016/j.vaccine.2018.10.041
Fig. 1. Theoretical causal diagram for the relationships between maternal RSV vaccination, severe early infant RSV- lower respiratory infections, and later recurrent childhood
wheezing. The diagram illustrates how maternal vaccination against RSV may prevent the development of recurrent childhood wheezing (the endpoint) through preventing
an early severe RSV-related lower respiratory infection (LRI) during infancy (the mediator). Links between elements in the diagram and parameters in the sample size study
are described in the blue caption boxes. The sign labelling each arrow indicates the direction of association as positive (+) or negative () between the connecting nodes. If the
relationship between early severe RSV-LRI and recurrent childhood wheezing is confounded by a predisposition to respiratory infections, then observational studies
estimating the increased risk of recurrent childhood wheezing due to early RSV-LRI may be overestimated.
C.A. Riddell et al. / Vaccine xxx (xxxx) xxx 3inputs for our model: (1) baseline attack rate of severe early RSV, r;
(2) vaccine efficacy, VE; (3) risk of recurrent wheezing during child-
hood, w; and (4) risk ratio for recurrent wheezing according to
early RSV illness, RRRW (Fig. 1). We also considered two allocation
schemes, 1:1 and 2:1.2.2. Baseline attack rate of early severe RSV
Up to two-thirds of infants acquire RSV during their first year of
life [5]. Only a proportion of these illnesses is preventable by
maternal immunization, as passive protection from maternal anti-
bodies wanes with time and are not expected to exceed 6 months
[1]. For simplicity, we assumed that subclinical or mild early RSV
illness would have a very weak association, if any, with develop-
ment of later recurrent childhood wheezing. We found the most
stable estimates of severe RSV incidence during this risk period
were for infants younger than 6 months of age. Thus, we used esti-
mates of the baseline RSV attack rate during the first 6 months of
life that resulted in the more severe outcomes of LRI or hospitaliza-
tion. In this report, we use ‘‘early severe RSV illness” to define RSV
illness during the first 6 months of life that resulted in LRI or
hospitalization.
A recent meta-analysis estimated that between 6.3% and 16.9%
of infants acquired a RSV-related LRI in the first 6 months of life
across world income strata [4]. The rate of hospitalization in coun-
tries with adequate access to medical care may best reflect the
attack rate of the most severe illnesses. RSV-hospitalization esti-
mates for most income strata were greater than 2% between 0
and 5 months of age, with the upper bound of 2.7%. We used values
of 2.7%, 6.0%, and 17.0% as attack rates of early severe RSV illness.2.3. Vaccine efficacy
There is no information currently available on the efficacy of
candidate maternal RSV vaccines. The WHO Preferred Product
Characteristics for RSV Vaccines specifies that a vaccine with 50%
efficacy would be favourable, while greater than 70% efficacy
would be preferred [1,2]. We used values of 50.0%, 70.0%, and
90.0%.Please cite this article as: Corinne A. Riddell, Niranjan Bhat, Louis J. Bont et al.,
tion during pregnancy to prevent recurrent childhood wheezing: A sample siz2.4. Baseline risk of recurrent wheezing among children unexposed to
early severe RSV illness
Estimates for recurrent childhood wheezing vary widely across
countries and represent the overall rate of recurrent wheezing in a
population, independent of early RSV status. We were unable to
find global estimates of recurrent childhood wheeze for children
aged up to 3 years. As a proxy, we used the International Study
of Asthma and Allergies in Childhood (ISAAC) survey which reports
the most recent international estimates for ‘‘symptoms of severe
asthma” among children aged 6–7 years, which was the youngest
age group ISAAC studied. Children had these symptoms if they
had current wheeze and reported any of the following: 4 attacks
of wheeze, 1 night/week of sleep disturbance from wheeze, or
wheeze-affected speech, within the previous year. The global
prevalence of these symptoms among this age group was 4.9%,
with the highest prevalence in the Oceanic region (9.5%), and the
highest centre rate in Costa Rica (20.3%). We used parameter
inputs of 4.9%, 9.5%, and 20.0%.
We expect the actual prevalence of recurrent wheezing at
3 years to be higher than the prevalence of these symptoms
reported among 6–7 years. Furthermore, these estimates do not
account for early RSV exposure status, even though we require
estimates among children unexposed to early severe RSV illness.
These overall estimates will approximate the estimate among the
unexposed when the exposed population is small (i.e., for small
baseline attack rates of severe early RSV) or when RRRW is low.
Otherwise, they would be overestimates. We therefore chose a
wide range of recurrent wheezing prevalence estimates to reflect
these opposing measurement uncertainties.2.5. Risk ratio of recurrent wheezing according to RSV status
If RSV vaccination during pregnancy leads to reduction in later
recurrent childhood wheezing, we assume the effect occurs by pre-
venting early severe RSV illness among infants. The gold standard
study design for estimating a causal risk ratio between early severe
RSV illness and recurrent childhood wheezing would be a RCT of
RSV prevention with predefined outcomes, however there have
been few such trials conducted [19,20]. Several observationalInforming randomized clinical trials of respiratory syncytial virus vaccina-
e analysis, Vaccine, https://doi.org/10.1016/j.vaccine.2018.10.041
Fig. 2. Illustration of the parameters used to estimate risk ratios and sample size in
clinical trials of maternal RSV immunization on development of later recurrent
childhood wheezing. Each filled dot in this figure represents a mother-infant pair,
with the colour representing their RSV infection status and black outline indicating
infants who go on to develop recurrent childhood wheezing. There are 100 rows of
10 dots, to represent 1000 mother-infant pairs randomized each to placebo and
vaccination. Following the in-text example, 20% of placebo (200 mother-infant
pairs; purple dots) acquire early and severe infant RSV vs. 10% in the immunized
arm (100 mother infant pairs; purple dots), for a vaccine efficacy of 50%. If early RSV
illness increases the later development of recurrent childhood wheezing, then the
proportion of children who develop recurrent wheezing will be higher among those
with early RSV. This is shown by the higher density of recurrent wheezing cases
(black outline) among those with RSV illness (purple dots) vs. those without (blue
dots). Summing the wheezing cases, there are 60 cases among the 300 infants who
acquired RSV (for a 20% risk) vs. 85 wheezing cases among the 1700 infants who did
not acquire RSV (for a 5% risk) giving rise to four-fold increased risk of wheezing in
children exposed vs. unexposed to early and severe infant RSV. This example shows
80 cases of childhood recurrent wheezing among the placebo arm vs. 65 among the
immunized arm for a risk ratio between vaccination and childhood recurrent
wheezing (RRVW) of 081.
4 C.A. Riddell et al. / Vaccine xxx (xxxx) xxxstudies have assessed the risk of recurrent wheezing associated
with RSV-related hospitalizations in infancy, but they are at risk
of confounding bias, particularly from factors predisposing infants
to severe RSV illness and later development of wheezing, such as
poor lung function. A 2017 systematic review summarizing these
studies reported risk ratios between 1.7 and 3.3 for recurrent
wheezing occurring 3–5 years after RSV-hospitalization during
infancy [21]. However, risk ratios as high as 4.3 were estimated
for recurrent childhood wheezing after only one year of follow-
up [21]. We used RRRW parameter inputs of 1.6, 2.6, and 4.0.2.6. Calculation of effect size, sample size, and number needed to treat
For each combination of the parameter estimates (summarized
in Table 1), we calculated the risk of recurrent childhood wheezing
in each of the placebo and active vaccine arms. From these risks,
we calculated RRVW, the corresponding risk ratio for maternal
RSV vaccination and recurrent childhood wheezing. These riskPlease cite this article as: Corinne A. Riddell, Niranjan Bhat, Louis J. Bont et al.,
tion during pregnancy to prevent recurrent childhood wheezing: A sample sizratios are the effect sizes that a trial would be designed to detect,
with larger sample sizes needed to detect smaller effect sizes
(i.e., RRVW closer to 1). We did not consider the time-varying rela-
tionships between gestational timing of maternal vaccination,
birth, and RSV seasonality [22], as maternal vaccine RCTs with
paediatric RSV endpoints are expected to time vaccination to max-
imize transplacental antibody transport and births occurring dur-
ing the RSV season.
To calculate the sample size required to detect a difference
between these risks, we performed a two-sided sample size calcu-
lation assuming 80% statistical power and 5% type I error, under a
1:1 or a 2:1 vaccine allocation to active vaccine and placebo arms,
respectively. These calculations were performed using the power.
prop.test function from the stats package, and the bsamsize function
from the Hmisc package in R version 3.4.2 [23]. To estimate the
number of pregnant women needed to be vaccinated to prevent
one case of recurrent childhood wheezing, we calculated the abso-
lute difference in risk of recurrent childhood wheezing in vacci-
nated and unvaccinated mother-infant pairs (i.e., the number of
excess cases per 100 unvaccinated women) and took the inverse
of this value.
2.7. Scenario plausibility
While the parameter inputs reflect a range of evidence-based
estimates, some combinations of parameter values resulted in sce-
narios that were unlikely, particularly when multiple extreme
parameters were considered simultaneously. Scenarios that
combined a baseline risk of recurrent wheezing of 20.0% with a
4.0-fold increase in risk of recurrent wheezing following a severe
early RSV illness were categorized as ‘‘least likely” since this would
imply that 80% of children who had an early severe RSV illness
would later develop recurrent wheezing, which we deemed unrea-
sonably high. Furthermore, scenarios that combined a 2.6-fold or
4.0-fold increase in risk of recurrent wheezing and a 17.0% attack
rate of early severe RSV illness were categorized as ‘‘less likely”
or ‘‘least likely”, respectively. This is because these risk ratios esti-
mates were based on the association between RSV-hospitalization
and recurrent childhood wheezing, while 17.0% referred to all
RSV-LRIs, not just hospitalizations (which is 6 times higher than
the estimated RSV-hospitalization rate of 2.7%). All other scenarios
were categorized as ‘‘more plausible”.
2.8. Data sharing
All of the statistical code to perform these calculations and
reproduce this manuscript is publicly available on GitHub:
https://github.com/corinne-riddell/RSV-wheeze-sample-size/.
2.9. Role of funding source
The funders played no role in study design, interpretation of the
data, the writing of the report, or the decision to submit the manu-
script for publication. The corresponding author had full access to
all the data in the study and had final responsibility for the
decision to submit for publication.3. Results
There were 81 scenarios for each of the 1:1 and 2:1 allocation
schemes. Under each scheme, 57 were categorized as more plausi-
ble, 9 as less likely, and 15 as least likely due to the presence of
extreme parameters considered simultaneously (Table 2). Of all
scenarios, 70% had vaccine effect sizes (RRVW) between 0.9 and
1.0, with effect sizes nearest to 1.0 being the most difficult toInforming randomized clinical trials of respiratory syncytial virus vaccina-
e analysis, Vaccine, https://doi.org/10.1016/j.vaccine.2018.10.041
Table 1
Parameters used in sample size calculations.
Variable Values Rationale for chosen values
Severe early RSV attack rate 2.7%,
6.0%,
17.0%
While up to two-thirds of infants acquire RSV in their first year of life, many of these infections are
subclinical. We assume that the RSV illnesses on the causal pathway to recurrent childhood
wheezing are therefore a subset of the more severe illnesses. Shi et al [4] reported comprehensive,
regional estimates for RSV-associated lower respiratory infections (RSV-LRI). These estimates span
63.3–168.9 RSV-LRI per 1000 infants (6.3–16.9%, rounded to 6.0% and 17.0% in our models) across
the income regions. The lowest estimate (63.3/1000) was for lower-middle income countries, while
the highest estimate was from upper-middle income countries (168.9/1000). However, the order of
estimates was not aligned with income level (i.e., the lowest income countries had estimates
between those of lower-middle income countries and upper-middle income countries). The lowest
estimate was 0.7% from lower income countries, which we expect to be spuriously low due to due to
decreased healthcare utilisation in such settings.
Shi et al [4] also provided estimate for RSV-LRI hospitalizations. These estimates were >20.2/1000
for all income regions except the low-income region. 27.1/1000 (2.7%) reflects the estimate for
industrialized regions. This may reflect the most appropriate attack rate if only the most severe RSV-
LRI lead to later recurrent childhood wheezing
Vaccine efficacy 50.0%,
70.0%,
90.0%
There is no information on the potential efficacy on candidate RSV vaccines. However, the WHO
specified that a vaccine with 50.0% efficacy would be considered, while greater than 70.0% efficacy is
preferred [1]. We also consider a 90.0% efficacy point as an upper bound
Vaccine allocation scheme 1:1,
2:1
The allocation scheme denotes the number of mother-infant pairs randomized to receive vaccine vs.
placebo. The chosen schemes (1:1 and 2:1) are the most common ones used in randomized
controlled trials
Baseline risk of recurrent childhood wheezing 4.9%,
9.5%,
20.0%
Recurrent childhood wheezing prevalence varies substantially by country. The International Study
of Asthma and Allergies in Childhood (ISAAC) reported prevalence rates of asthma, recurrent
wheezing, and current wheezing for 6–7-year olds and 13–14-year olds [29]. The global rate of
recurrent wheezing among 6–7-year olds is 4.9%. Regionally, the highest rate was 9.5% in Oceania,
similar to the rate for other English-speaking centres. The highest centre rate was 20.3% in Costa
Rica, while the lowest regional rate was 3.2% in Asia-Pacific. For the study we use 4.9%, 9.5%, and
20.0% to cover this range. Sample size requirements will be larger in areas with lower than a 4.9%
baseline risk of recurrent wheezing
Risk ratio for the association between early RSV-
LRI and recurrent childhood wheezing
1.6,
2.6,
4.0
A 2017 systematic review by Fauroux and colleagues examined the association between early RSV-
LRI hospitalization (RSV-h) and asthma/wheezing in Western countries. The RSV-hospitalization
occurred before 3 years of age, with most studies looking before 12 months, and asthma/wheezing
was measured later, in the shortest studies wheezing was measured after only a year of life, while
the longest studies measured asthma 30 years later. Most studies estimated a harmful association
(risk ratios > 1). For studies with follow-up of 6 years or fewer, the provided or calculated risk ratios
(RRs) ranged between 0.5 and 4.3. However, these were the RRs for RSV-LRI hospitalizations,
suggesting that RRs for RSV-LRI overall would have been lower. Risk ratios for the studies reported
in Fauroux, where the follow-up time is 6 years or less ranged from 0.5 to 4.3. Values used in the
sample size calculations: 1.6, 2.6, 4.0
Table 2
Estimated risk ratios for recurrent childhood wheezing in vaccinated vs. unvaccinated mother-infant pairs across several scenarios.1
Risk ratio between RSV and recurrent childhood wheezing2
Attack rate of severe early RSV3 Percent altered4 1.6 2.6 4.0
Vaccine efficacy of 50%
2.7% 1.4% 0.99 0.98 0.96
6.0% 3.0% 0.98 0.96 0.92
17.0% 8.5% 0.95 0.89 (Less likely) 0.83 (Least likely)
Vaccine efficacy of 70%
2.7% 1.9% 0.99 0.97 0.95
6.0% 4.2% 0.98 0.94 0.89
17.0% 11.9% 0.94 0.85 (Less likely) 0.76 (Least likely)
Vaccine efficacy of 90%
2.7% 2.4% 0.99 0.96 0.93
6.0% 5.4% 0.97 0.92 0.86
17.0% 15.3% 0.92 0.81 (Less likely) 0.70 (Least likely)
Notes:
1 This table does not present recurrent wheezing, w, as a parameter input because it cancels out in the calculation of the risk ratios (implying that these risk ratios hold for
every level of baseline risk of recurrent wheezing).
2 The risk ratios (RRRW) between RSV illness and recurrent childhood wheezing are estimated based on relationships between RSV-hospitalizations and later development
of recurrent childhood wheezing. Scenarios that combined a baseline risk of recurrent wheezing of 20.0% with a 4.0-fold increase in risk of recurrent wheezing following a
severe early RSV illness were categorized as ‘‘least likely”. Scenarios that combined a 4.0-fold or 2.6-fold increase in risk of recurrent wheezing and a 17.0% attack rate of early
severe RSV illness were categorized as ‘‘least likely” or ‘‘less likely”, respectively. All other scenarios are considered ‘‘more plausible”.
3 The largest attack rates (6.0% and 17.0%) are estimated based on the proportion of infants that acquired RSV-LRI between 0 and 5 months from community-based studies,
and the smallest attack rate corresponds to the portion of infants aged 0 to 5 months hospitalized for severe RSV.
4 The percent altered is the proportion of infants expected to have their RSV status affected by maternal vaccination during pregnancy in the vaccination arm and can be
calculated by multiplying the vaccine efficacy by the attack rate of severe, early RSV illness.
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Fig. 3. Minimal sample size required (per trial arm) to detect a difference in recurrent childhood wheezing for mother-infant pairs vaccinated against RSV under a 1:1
allocation scheme across several scenarios. This figure illustrates the estimated risk ratio between vaccination and recurrent wheezing (RRVW, on the x-axis) that results from
the parameters that define each scenario, indicated by the size, colour, line type, and panel. The corresponding sample size to detect the risk ratio is shown on the y-axis,
which is plotted on a log scale. Scenarios classified less likely are indicated with a cross (+), and those classified least likely are denoted with an asterisk (⁄).
6 C.A. Riddell et al. / Vaccine xxx (xxxx) xxxdetect. The less likely and least likely scenarios had the lowest
RRVW values.
The sample size requirements increase as a function of vaccine
effect size (RRVW), becoming larger as the effect size diminishes.Table 3
Estimated risk ratios and total sample size requirements for each scenario according to th
Vaccine efficacy Severe and early 
RSV attack rate
Percent 
altered
Risk of 
recurrent 
wheezing 
among 
unexposed2
Risk ratio 
RSV- recur
childhoo
wheezing
50.0% 2.7% 1.35% 4.9%
50.0% 2.7% 1.35% 9.5%
50.0% 2.7% 1.35% 20.0%
50.0% 2.7% 1.35% 4.9%
50.0% 2.7% 1.35% 9.5%
50.0% 2.7% 1.35% 20.0%
50.0% 2.7% 1.35% 4.9%
50.0% 2.7% 1.35% 9.5%
50.0% 2.7% 1.35% 20.0%
50.0% 6.0% 3.00% 4.9%
50.0% 6.0% 3.00% 9.5%
50.0% 6.0% 3.00% 20.0%
50.0% 6.0% 3.00% 4.9%
50.0% 6.0% 3.00% 9.5%
50.0% 6.0% 3.00% 20.0%
50.0% 6.0% 3.00% 4.9%
50.0% 6.0% 3.00% 9.5%
50.0% 6.0% 3.00% 20.0%
50.0% 17.0% 8.50% 4.9%
50.0% 17.0% 8.50% 9.5%
50.0% 17.0% 8.50% 20.0%
50.0% 17.0% 8.50% 4.9%
50.0% 17.0% 8.50% 9.5%
50.0% 17.0% 8.50% 20.0%
Please cite this article as: Corinne A. Riddell, Niranjan Bhat, Louis J. Bont et al.,
tion during pregnancy to prevent recurrent childhood wheezing: A sample sizFig. 3 illustrates the required sample size per trial arm for each sce-
nario under the randomization scheme of 1:1. Among the more
plausible scenarios, the sample size required per arm ranges
between 6196 and 4.7 million, with 75% of plausible scenarioseir randomization scheme.1
for 
rent 
d 
2
Risk ratio for 
vaccination-
recurrent 
childhood 
wheezing2
Total sample 
size required 
under 1:1 
randomization
Total sample 
size required 
under 2:1 
randomization
Number 
needed to 
vaccinate
1.6 0.99 9,394,094 10,563,023 2,519
1.6 0.99 4,608,006 5,181,541 1,299
1.6 0.99 1,931,439 2,172,005 617
2.6 0.98 1,346,066 1,512,325 944
2.6 0.98 659,557 741,079 487
2.6 0.98 275,634 309,768 231
4.0 0.96 392,818 440,855 503
4.0 0.96 192,182 215,715 259
4.0 0.96 79,979 89,808 123
1.6 0.98 1,928,735 2,167,427 1,133
1.6 0.98 945,332 1,062,391 584
1.6 0.98 395,375 444,412 277
2.6 0.96 282,454 316,863 425
2.6 0.96 138,103 154,954 219
2.6 0.96 57,377 64,408 104
4.0 0.92 84,786 94,906 226
4.0 0.92 41,313 46,259 116
4.0 0.92 17,001 19,054 55
1.6 0.95 251,193 281,747 400
1.6 0.95 122,789 137,749 206
1.6 0.95 50,980 57,220 98
2.6 0.89 39,246 43,837 150
2.6 0.89 19,050 21,289 77
2.6 0.89 7,756 8,680 36
Informing randomized clinical trials of respiratory syncytial virus vaccina-
e analysis, Vaccine, https://doi.org/10.1016/j.vaccine.2018.10.041
Table 3 (continued)
50.0% 17.0% 8.50% 4.9% 4.0 0.83 12,698 14,119 80
50.0% 17.0% 8.50% 9.5% 4.0 0.83 6,102 6,791 41
50.0% 17.0% 8.50% 20.0% 4.0 0.83 2,413 2,693 19
70.0% 2.7% 1.89% 4.9% 1.6 0.99 4,785,632 5,380,025 1,799
70.0% 2.7% 1.89% 9.5% 1.6 0.99 2,347,659 2,639,353 928
70.0% 2.7% 1.89% 20.0% 1.6 0.99 984,249 1,106,663 440
70.0% 2.7% 1.89% 4.9% 2.6 0.97 684,046 768,122 674
70.0% 2.7% 1.89% 9.5% 2.6 0.97 335,252 376,498 348
70.0% 2.7% 1.89% 20.0% 2.6 0.97 140,193 157,487 165
70.0% 2.7% 1.89% 4.9% 4.0 0.95 198,969 223,078 359
70.0% 2.7% 1.89% 9.5% 4.0 0.95 97,386 109,208 185
70.0% 2.7% 1.89% 20.0% 4.0 0.95 40,576 45,527 88
70.0% 6.0% 4.20% 4.9% 1.6 0.98 980,780 1,101,662 809
70.0% 6.0% 4.20% 9.5% 1.6 0.98 480,803 540,111 417
70.0% 6.0% 4.20% 20.0% 1.6 0.98 201,196 226,069 198
70.0% 6.0% 4.20% 4.9% 2.6 0.94 142,889 160,106 303
70.0% 6.0% 4.20% 9.5% 2.6 0.94 69,900 78,341 156
70.0% 6.0% 4.20% 20.0% 2.6 0.94 29,082 32,615 74
70.0% 6.0% 4.20% 4.9% 4.0 0.89 42,611 47,594 161
70.0% 6.0% 4.20% 9.5% 4.0 0.89 20,783 23,224 83
70.0% 6.0% 4.20% 20.0% 4.0 0.89 8,575 9,595 39
70.0% 17.0% 11.90% 4.9% 1.6 0.94 127,011 142,282 285
70.0% 17.0% 11.90% 9.5% 1.6 0.94 62,120 69,606 147
70.0% 17.0% 11.90% 20.0% 1.6 0.94 25,830 28,963 70
70.0% 17.0% 11.90% 4.9% 2.6 0.85 19,598 21,821 107
70.0% 17.0% 11.90% 9.5% 2.6 0.85 9,527 10,615 55
70.0% 17.0% 11.90% 20.0% 2.6 0.85 3,895 4,348 26
70.0% 17.0% 11.90% 4.9% 4.0 0.76 6,255 6,917 57
70.0% 17.0% 11.90% 9.5% 4.0 0.76 3,014 3,337 29
70.0% 17.0% 11.90% 20.0% 4.0 0.76 1,201 1,335 14
Vaccine efficacy Severe and early 
RSV attack rate
Percent 
altered
Risk of 
recurrent 
wheezing 
among 
unexposed2
Risk ratio for 
RSV- recurrent 
childhood 
wheezing2
Risk ratio for 
vaccination-
recurrent 
childhood 
wheezing2
Total sample 
size required 
under 1:1 
randomization
Total sample 
size required 
under 2:1 
randomization
Number 
needed to 
vaccinate
(continued on next page)
C.A. Riddell et al. / Vaccine xxx (xxxx) xxx 7requiring more than 31,060 mother-infant pairs per trial arm, and
47% requiring more than 100,000 mother-infant pairs per trial arm.
With a vaccine efficacy of 50%, the plausible scenarios would
require at least 20,657 mother-infant pairs per arm to detect an
effect of RSV maternal vaccination on recurrent wheezing. Less
likely scenarios require between 1159 and 5799 pairs per arm
among those with 90% vaccine efficacy, and between 3878 and
19,623 pairs per arm among those with 50% vaccine efficacy. The
least likely scenarios require sample sizes ranging between 354
and 39,990 per trial arm. The total sample size under each scenario
is provided in Table 3. Larger sample sizes would be required for
study designs using 2:1 randomization as compared to 1:1 ran-
domization (Table 3).
Fig. 4 displays the number of women who need to be vaccinated
in order to prevent one case of recurrent childhood wheezing
under each of the considered scenarios with 1:1 vaccine allocation.
Among the more plausible scenarios, at least 54 women need to be
vaccinated to prevent one case. Seventy-five percent of these plau-
sible scenarios require at least 147 women to prevent one case,
while 25% require more than 503 women. Scenarios classified asPlease cite this article as: Corinne A. Riddell, Niranjan Bhat, Louis J. Bont et al.,
tion during pregnancy to prevent recurrent childhood wheezing: A sample sizless likely require between 20 and 150 women, while scenarios
classified as least likely require between 10 and 123 women. The
number needed to vaccinate for each allocation scenario is pro-
vided in Table 3.4. Discussion
Most maternal RSV immunization scenarios that we evaluated
resulted in very small vaccine effect sizes measuring the impact
on recurrent childhood wheezing (i.e., RRVW > 0.9) in general pop-
ulations, and they would require unfeasibly large sample sizes to
detect significant differences between trial arms. The scenarios
considered more plausible required sample sizes of at least 6196
per trial arm, with most of these scenarios requiring substantially
larger sample sizes. All of the more plausible scenarios exceed the
size of the only current phase III trial of RSV vaccination in preg-
nant women, which has a total planned sample size of 8618 ran-
domized in 2:1 vaccine to placebo allocation [24]. Our sample
size calculations indicate the improbability of RCTs conducted forInforming randomized clinical trials of respiratory syncytial virus vaccina-
e analysis, Vaccine, https://doi.org/10.1016/j.vaccine.2018.10.041
Table 3 (continued)
90.0% 2.7% 2.43% 4.9% 1.6 0.99 2,890,612 3,248,972 1,399
90.0% 2.7% 2.43% 9.5% 1.6 0.99 1,418,153 1,594,049 721
90.0% 2.7% 2.43% 20.0% 1.6 0.99 594,696 668,552 342
90.0% 2.7% 2.43% 4.9% 2.6 0.96 412,158 462,564 524
90.0% 2.7% 2.43% 9.5% 2.6 0.96 202,046 226,787 270
90.0% 2.7% 2.43% 20.0% 2.6 0.96 84,543 94,931 128
90.0% 2.7% 2.43% 4.9% 4.0 0.93 119,487 133,829 279
90.0% 2.7% 2.43% 9.5% 4.0 0.93 58,508 65,548 144
90.0% 2.7% 2.43% 20.0% 4.0 0.93 24,406 27,362 68
90.0% 6.0% 5.40% 4.9% 1.6 0.97 591,333 663,914 629
90.0% 6.0% 5.40% 9.5% 1.6 0.97 289,942 325,567 324
90.0% 6.0% 5.40% 20.0% 1.6 0.97 121,392 136,350 154
90.0% 6.0% 5.40% 4.9% 2.6 0.92 85,699 95,910 236
90.0% 6.0% 5.40% 9.5% 2.6 0.92 41,945 46,957 121
90.0% 6.0% 5.40% 20.0% 2.6 0.92 17,475 19,580 57
90.0% 6.0% 5.40% 4.9% 4.0 0.86 25,384 28,289 125
90.0% 6.0% 5.40% 9.5% 4.0 0.86 12,392 13,819 64
90.0% 6.0% 5.40% 20.0% 4.0 0.86 5,127 5,726 30
90.0% 17.0% 15.30% 4.9% 1.6 0.92 76,138 85,183 222
90.0% 17.0% 15.30% 9.5% 1.6 0.92 37,259 41,698 114
90.0% 17.0% 15.30% 20.0% 1.6 0.92 15,515 17,380 54
90.0% 17.0% 15.30% 4.9% 2.6 0.81 11,597 12,869 83
90.0% 17.0% 15.30% 9.5% 2.6 0.81 5,645 6,270 42
90.0% 17.0% 15.30% 20.0% 2.6 0.81 2,317 2,580 20
90.0% 17.0% 15.30% 4.9% 4.0 0.70 3,648 4,009 44
90.0% 17.0% 15.30% 9.5% 4.0 0.70 1,762 1,940 22
90.0% 17.0% 15.30% 20.0% 4.0 0.70 708 783 10
Vaccine efficacy Severe and early 
RSV attack rate
Percent 
altered
Risk of 
recurrent 
wheezing 
among 
unexposed2
Risk ratio for 
RSV- recurrent 
childhood 
wheezing2
Risk ratio for 
vaccination-
recurrent 
childhood 
wheezing2
Total sample 
size required 
under 1:1 
randomization
Total sample 
size required 
under 2:1 
randomization
Number 
needed to 
vaccinate
Note:
1Scenarios that combined a baseline risk of recurrent wheezing of 20.0% with a 4.0-fold increase in risk of recurrent wheezing following a severe early RSV illness were
categorized as ‘‘least likely”. Scenarios that combined a 4.0-fold or 2.6-fold increase in risk of recurrent wheezing and a 17.0% attack rate of early severe RSV illness were
categorized as ‘‘least likely” or ‘‘less likely”, respectively. ‘‘Least likely” scenarios are shaded in dark grey and ‘‘less likely” scenarios are shaded in light grey.
2In the report text, these abbreviations for the parameters were used: w (baseline risk of recurrent wheezing among unexposed at 3 years), RRRW (risk ratio for RSV- recurrent
childhood wheezing), RRVW (risk ratio for vaccination- recurrent childhood wheezing, or the vaccine effect size).
Fig. 4. Number needed to vaccinate to prevent one case of recurrent childhood wheezing under a 1:1 allocation scheme across several scenarios. This figure illustrates the
estimated risk ratio between vaccination and recurrent wheezing (RRVW, on the x-axis) that results from the parameters that define each scenario, as indicated by the size,
colour, line type, and panel. The corresponding number of pregnant women requiring vaccination to prevent one case of recurrent childhood wheezing is shown on the y-axis,
which is plotted on a log scale. Scenarios classified less likely are indicated with a cross (+), and those classified least likely are denoted with an asterisk (⁄).
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C.A. Riddell et al. / Vaccine xxx (xxxx) xxx 9licensure of RSV vaccines for use by pregnant women in general
populations to prevent recurrent childhood wheezing. Trials with
asthma endpoints would likely need to be even larger.
While our goal was to inform public health about the potential
impact of RSV vaccines during pregnancy, our findings may be gen-
eralized to trials of anti-RSV monoclonal antibodies or paediatric
RSV vaccination. Two RSV monoclonal antibody RCTs designed to
demonstrate prevention of RSV illness in infants were extended
to monitor participants for medically-attended wheezing at 3 years
[19] or asthma at 6 years [20]. Both trials were powered to detect
RSV prevention on a reduction in wheezing days within the first
year of life, and not later childhood respiratory outcomes. In a
RCT conducted among 2127 Native American infants in the United
States, 14.9% of children in the treated group and 14.0% in the pla-
cebo group experienced serious early childhood wheezing between
1 and 3 years, of which only 3% in either arm had 3 or more
medically-attended wheezing episodes [25]. In the RCT conducted
in the Netherlands, of 429 children who were followed to age 6,
10.3% in the RSV prevention arm had physician-diagnosed asthma
at 6 years vs. 9.9% in the placebo arm. No difference in mean forced
expiratory volume was detected [20]. Our results indicate that
these studies were substantially smaller than what would be nec-
essary to demonstrate a significant effect on RSV-caused respira-
tory outcomes. Furthermore, the small differences in respiratory
outcomes across treatment arms suggest that even larger sample
sizes would be required if the true RRRW is lower than 1.6, the
lower bound of the parameter included in this study.
Whether early RSV illness causes later recurrent wheezing is
still unclear. Even assuming a moderate to strong risk ratio of
RSV illness associated with wheezing illness (RRRW between 1.6
and 4.0), our calculations indicate that the magnitude of vaccine
effect on recurrent wheezing is likely small. However, the global
burden of asthma as a lifelong chronic disease is sufficiently large
that even a small reduction in asthma incidence would have major
public health implications. Alternative study designs can overcome
the sample size constraints of RCTs, and have been used to esti-
mate the causal effect of maternal vaccination on a spectrum of
childhood outcomes. However, caution should be taken in the
design and interpretation of observational vaccine effectiveness
studies. For example, confounding by health status led to unrealis-
tic effect estimates of influenza vaccination on pneumonia among
the elderly [26], and such studies still influence current global vac-
cine policy recommendations [27]. More objective measures of
wheezing and asthma outcomes, such as physician’s diagnosis
and lung function studies, can minimize differential measurement
bias that can occur with parental reporting [28]. Planning in
advance by engaging clinical experts, vaccinologists, and observa-
tional research methodologists is crucial to increase the quality
and reliability of studies to best inform public health decisions.
Our investigation has its limitations. This analysis did not
account for loss to follow-up, which is likely to occur for multiyear
studies. For the purposes of our analyses, we assumed a causal link
between infant RSV exposure and childhood recurrent wheezing,
and the parameter choices represented a range of published esti-
mates. Although we used estimates from systematic reviews,
meta-analyses, and ISAAC surveys to obtain parameter inputs for
our model, each of these is subject to its own weaknesses. While
most stable estimates of severe RSV incidence were only available
for infants younger than 6 months of age, passive protection from
maternal antibodies wanes with time and may only last up to
2 months of age [13]. Data from the ongoing phase III clinical trial
of RSV vaccination in pregnant women will provide valuable infor-
mation on severe, early RSV attack rate and on vaccine efficacy
which may refine our estimates once they are published [24]. To
evaluate the risk of recurrent wheezing, we used prevalence esti-
mates for symptoms of severe asthma (which includes recurrentPlease cite this article as: Corinne A. Riddell, Niranjan Bhat, Louis J. Bont et al.,
tion during pregnancy to prevent recurrent childhood wheezing: A sample sizwheezing) for 6–7 year-olds, which likely underestimate the
prevalence among 3 year-olds. However, we calculated sample
sizes for a wide range of inputs for recurrent wheezing to under-
score its uncertainty and worldwide variation. Practically speaking,
an even earlier recurrent wheezing endpoint (i.e., at 12–24 months
of age) may be desired to keep trial costs and participant attrition
low. However, diagnosis of wheezing is subjective and variable at
these ages, and we were unable to find suitable disease rate esti-
mates to investigate these earlier endpoints. If studies are planned
to consider recurrent wheeze outcomes in children 2–3 years of
age, and baseline rates are known, our tables may still provide
guidance about whether sample size is sufficient so long as the
expected parameter values are close to those we investigated.
A safe maternal RSV vaccine that prevents acute RSV illness in
early infancy would be a major public health accomplishment
due to the high burden of RSV illness in young children globally.
Based on our analysis, RCTs for candidate maternal RSV vaccines
undertaken for licensure are unlikely to demonstrate an effect on
recurrent wheezing illness due to the large sample sizes needed
to demonstrate a significant effect. Further efforts are needed to
plan for post-licensure studies to inform public health expectations
regarding the impact of RSV vaccines given during pregnancy.
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